RxDoctor Payments DataLook up a doctor →

Lawrence Rice, MD

Hematology · Houston, TXNPI 1588758510

Payments from drug & device makers

$378,218in general payments, 2019–2025

Across 451 payments — averaging $838.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Agios Pharmaceuticals, Inc.$139K
  • Novartis$129K
  • AstraZeneca$42K
  • Takeda Pharmaceuticals U.S.A., Inc.$35K
  • Sanofi$9K
  • Dova Pharmaceuticals$5K
  • plus $19K from 40 others
$452in research payments, 2019–2025

Across 13 payments — averaging $34.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shire North American Group Inc$452

What the payments were for

  • Consulting fees$62,47760%
  • Speaking & faculty fees$30,13829%
  • Travel & lodging$1,2431%
  • Food & beverage$9,3529%
  • Education$1320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$378,218 in reported general payments places this provider in the 80th percentile of 97 hematology providers in Texas.

See all hematology providers in Texas

Medicare billing

Part B allowed, 2024
$100,101
Medicare patients
284
Services billed
886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PyrukyndMitapivat Sulfate13$351,622
ImbruvicaIbrutinib13$211,226
PromactaEltrombopag Olamine13$140,441
TasignaNilotinib Hcl12$118,321
BosulifBosutinib12$115,225
EliquisApixaban77$79,354
XareltoRivaroxaban52$46,449
Hydroxyurea44$744
Prednisone20$138
Allopurinol11$67

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Agios Pharmaceuticals, Inc.Pyrukynd$139,277$351,62213 claims
NovartisPromacta, Tasigna$129,255$258,76225 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$92$211,22613 claims
PfizerBosulif, Eliquis$458$194,57989 claims
Johnson & JohnsonXarelto$1,474$46,44952 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 97 hematology providers in Texas.

Other hematology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →